{
    "nct_id": "NCT06137183",
    "official_title": "A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis",
    "inclusion_criteria": "* Diagnosis of UC for at least 3 months\n* Moderately to severely active UC, assessed by mMS\n* Inadequate response, loss of response to, or intolerance to conventional or advanced therapies for UC\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of Crohn's disease or indeterminate colitis\n* Suspicion of ischemic, radiation, microscopic, or infectious colitis\n* Prior colectomy\n* Inadequate response or loss of response to previous treatment of UC with tofacitinib, upadacitinib, or other systemic janus kinase (JAK) inhibitor",
    "miscellaneous_criteria": ""
}